Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
Édouard Januel(Inserm), Pierre Labauge, de Sèze(Université de Strasbourg), Kévin Bigaut(Hôpital Civil, Strasbourg), Céline Louapre(Inserm), Patrick Vermersch(Université de Lille), Julie Pique(Hospices Civils de Lyon), Bertrand Bourre(Hôpital Charles-Nicolle), Vito A. G. Ricigliano(Inserm), Jean Pelletier(Hôpital de la Timone), Philippe Kerschen(Centre Hospitalier Universitaire Henri-Mondor), Laurent Kremer, Caroline Bensa(Fondation Ophtalmologique Adolphe de Rothschild), Éric Berger, Salimata Gassama(Université de Rouen Normandie), Nathalie Derache, Sandra Vukusic(Hospices Civils de Lyon), Bertrand Audoin(Centre National de la Recherche Scientifique), P.-Y. Garcia, Adil Maarouf(Centre National de la Recherche Scientifique), S. Beltran(Centre Hospitalier Universitaire de Tours), Olivier Heinzlef(Centre Hospitalier Intercommunal de Poissy), Aude Maurousset
Cited by 18
Related Papers
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.
|Journal of Neurology Neurosurgery & Psychiatry|1992|1.8k
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging
|Journal of the Neurological Sciences|1993|930